The French pharmaceutical group has raised its earnings outlook as it reported a jump in second-quarter profit on a strong showing by its biotech unit and stronger sales of diabetes treatments.
from WSJ.com: US Business http://ift.tt/1ABwSkV
via IFTTT
from WSJ.com: US Business http://ift.tt/1ABwSkV
via IFTTT
No comments:
Post a Comment